Biosimilars, Vaccines and White Paper

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Biosimilars

Vaccines

White Paper

Quality by design with a focus on biosimilars

Pharmaceutical Technology

OCTOBER 28, 2022

Practising QbD in biosimilar product development. One area in which QbD should be practised is that of biosimilars, also known as follow-on biologics or subsequent entry biologics. Biosimilars are biologic medical products that almost exactly replicate products already being manufactured by other companies.

Pharma’s post-pandemic launch performance problem: what’s the prognosis?

pharmaphorum

JUNE 29, 2022

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. The prescription medicine market has recovered from the wild swings of the early pandemic with renewed growth.

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Vaccines Pharmaceutical Companies Pharmaceutical Companies

Pharmacist Digest

Quality by design with a focus on biosimilars

Pharma’s post-pandemic launch performance problem: what’s the prognosis?

Stay Connected